NRx Pharmaceuticals, Inc. announced that it has regained compliance with the Nasdaq minimum market value of listed securities (MVLS) requirement. The company received written notice from the Nasdaq Listing Qualifications Staff on January 17, 2025, confirming its compliance.
The company had previously been notified on August 6, 2024, that it was not in compliance with Nasdaq Listing Rule 5550(b)(2), having failed to maintain an MVLS of at least $35 million for 30 consecutive trading days.
NRx Pharmaceuticals met the compliance requirement on January 16, 2025, after its Common Stock maintained an MVLS of at least $35 million for a minimum of 10 consecutive trading days. This resolution closes the matter and ensures the company's continued listing on the Nasdaq Capital Market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.